A Non-randomized, Open-label, Prospective, Single-center Study of Apatinib Mesylate Tablet as Third-line and Later Therapy in Patients With Small Cell Cancer SCLC
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Rivoceranib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 18 Oct 2017 Results (n=10) presented at the 18th World Conference on Lung Cancer.
- 18 Oct 2017 According to results presented at the 18th World Conference on Lung Cancer, planned number of patient was 30 and from november 10, 2016 to june 18 2017, 10 patients were enrolled.
- 04 Sep 2017 Status changed from not yet recruiting to recruiting.